STOCK TITAN
  1. Home
  2. News
  3. KRTX

Karuna Therapeutics Inc - KRTX STOCK NEWS

Welcome to our dedicated news page for Karuna Therapeutics (Ticker: KRTX), a resource for investors and traders seeking the latest updates and insights on Karuna Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Karuna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Karuna Therapeutics's position in the market.

News
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
Rhea-AI Summary
Karuna Therapeutics, Inc. announces the NDA review for KarXT for schizophrenia treatment, Phase 3 trial results, key pipeline highlights, leadership appointments, financial results, and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
earnings
-
News
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
News
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Rhea-AI Summary
Bristol Myers Squibb (BMY) will acquire Karuna Therapeutics, Inc. (KRTX) for $14.0 billion, aiming to enhance their growth and diversify the portfolio in the neuroscience space. The transaction is expected to close in the first half of 2024, with KarXT, a first-in-class treatment for schizophrenia and Alzheimer's disease psychosis, as the key asset.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
News
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire Karuna Therapeutics, Inc. (KRTX) for $14 Billion, Expanding Its Portfolio in Neuroscience
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
News
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
Rhea-AI Summary
Karuna Therapeutics, a biopharmaceutical company (NASDAQ: KRTX), announced statistically significant and clinically meaningful improvements in positive and negative symptoms of schizophrenia with their drug KarXT. The dual M1/M4 muscarinic agonist showed a distinct tolerability profile and a potential to redefine the treatment landscape for schizophrenia. The Phase 3 EMERGENT-2 trial published in The Lancet demonstrated a 9.6-point reduction in PANSS total score compared to placebo, with a Prescription Drug User Fee Act (PDUFA) action date of September 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
acquisition clinical trial
-
News
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
News
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Rhea-AI Summary
Karuna Therapeutics, Inc. (NASDAQ: KRTX) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults, with a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024. If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades. The application is supported by positive data from the EMERGENT clinical trial program showing KarXT is associated with significant improvements in schizophrenia symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
News
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Rhea-AI Summary
Karuna Therapeutics (KRTX) announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT on 24-hour ambulatory blood pressure in adults with schizophrenia. KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg, ruling out a clinically meaningful increase in blood pressure. The trial showed that KarXT was generally well tolerated, with a side effect profile consistent with prior trials in the EMERGENT program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
clinical trial
-
News
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Rhea-AI Summary
Karuna Therapeutics, Inc. (NASDAQ: KRTX) announced positive results from its Phase 1b trial showing that KarXT (xanomeline-trospium) did not cause clinically meaningful increases in blood pressure in adults with schizophrenia. The trial demonstrated a mean decrease of -0.59 mmHg in 24-hour ambulatory systolic blood pressure, consistent with prior trials. The data confirms the cardiovascular safety profile of KarXT and will be included in the NDA Day 120 safety update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.77%
Tags
clinical trial
News
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
Rhea-AI Summary
Karuna Therapeutics announced the submission of a New Drug Application (NDA) to the FDA for KarXT for the treatment of schizophrenia. They also initiated Phase 3 trials for the treatment of psychosis in Alzheimer’s disease. The company expects $1.3 billion in cash to fund operations through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
earnings
Stock KRTX logo
Karuna Therapeutics Inc

Nasdaq:KRTX

KRTX Rankings

N/A Ranked by Market Cap
#3616 Ranked by Stock Gains
N/A Ranked by Dividends

KRTX Stock Data

12.60B
36.27M
4.99%
86.32%
5.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About KRTX

we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip